Se ha denunciado esta presentación.
Se está descargando tu SlideShare. ×

ATC Abstract 2006 C4d - THE INCIDENCE, IMPACT, AND MANAGEMENT OF HUMORAL REJECTION IN LUNG TRANSPLANTATION

Ad

American Transplant Congress
May 5-9 2007
Abstract Number: 952667
Keyword 1: Alloantibodies Keyword 2: Lung transplantatio...

Ad

ATC Abstract 2006 C4d - THE INCIDENCE, IMPACT, AND MANAGEMENT OF HUMORAL REJECTION IN LUNG TRANSPLANTATION
Cargando en…3
×

Eche un vistazo a continuación

1 de 2 Anuncio
1 de 2 Anuncio
Anuncio

Más Contenido Relacionado

Anuncio
Anuncio

ATC Abstract 2006 C4d - THE INCIDENCE, IMPACT, AND MANAGEMENT OF HUMORAL REJECTION IN LUNG TRANSPLANTATION

  1. 1. American Transplant Congress May 5-9 2007 Abstract Number: 952667 Keyword 1: Alloantibodies Keyword 2: Lung transplantation Keyword 3: Rejection Abstract Title: THE INCIDENCE, IMPACT, AND MANAGEMENT OF HUMORAL REJECTION IN LUNG TRANSPLANTATION Tarik Haddad, MD1 , Ramesh Kesavan, MD1 , Gnananandh Jayaraman, MD1 , Yavuz Silay, MD1 , George Noon, MD1 , Matthias Loebe, MD1 , Osama Gaber, MD2 , Nadine Haykal2 , Said Soubra, MD1 , Charlie Lan, DO1 , Phillip Cagle, MD2 , Anna Sienko, MD2 , Roberto Barrios, MD2 and Harish Seethamraju, MD1 . 1 Pulmonary and Critical Care, Baylor College of Medicine, Houston, TX, United States and 2 Pathology, Methodist Hospital, Houston, TX, United States. Body: Humoral rejection is associated with graft dysfunction in lung transplantation. We sought to determine the associated risk factors for the development of donor specific antibodies (DSA), use of c4d staining in detection for humoral rejection, and whether treatment of these patients results in graft improvement. During the period from January 2004 through June 2006, our center performed 55 lung transplants. A longitudinal prospective study was performed on these patients identifying the presence of panel reactive antibodies (PRA), DSA, and their associated risk factors. Of the identified group, patients with graft dysfunction marked by the presence of decreased spirometry values, dyspnea, or capillaritis underwent transbronchial biopsy with c4d staining by immunofluorescence. Patients identified with humoral rejection defined by presence of positive C4d staining, presence of DSA, and graft dysfunction underwent treatment with plasmapheresis, IVIG and rituximab. 19 post lung transplant patients with new elevations in PRA with either T or B cell class specificities or DSA with graft dysfunction were compared to patients without PRA and preserved graft function. There was no difference in the average age, race, transplant type, CMV status. Increased PRA post lung transplant was seen in female patients, use of cardiopulmonary bypass, and increased ventilator days. Within the positive PRA group, a subgroup was identified in which there was positive C4d staining (n=10). These two subgroups compared similarly with respect to age, sex, race, blood type, and CMV status. There was also increased presence of donor specific antibodies (7/10). Treatment for humoral rejection was performed in 4 patients. A significant improvement in FEV1 was seen in three patients with increases of FEV1 of 330cc, 290cc, and 100cc. One patient had resolution of PRA with treatment. It is too early to determine a similar response with the other patients. Humoral rejection is an important cause of graft dysfunction in lung transplant recipients. Risk factors such as female sex, use of cardiopulmonary bypass, and increased ventilator days were associated with increased PRA. Treatment of humoral rejection is associated with improvement in graft function.

×